Faricimab eye injections for untreated wet macular degeneration
Part of Eyes & vision clinical trials.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You must have a type of wet age-related macular degeneration (AMD) that has not been treated before and is currently active, with fluid in the center of the retina.
- Your starting vision (after correction) must be roughly between 20/32 and 20/320 on an eye chart.
- You must not have had any prior treatments for AMD, such as anti-VEGF injections, steroids, or laser therapy.
- You cannot have any other eye conditions (like glaucoma or significant scarring) that would prevent vision from improving.
- You must be able to have an eye exam and agree to the study visits and follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.